title: Macrophage fatty-acid synthase deficiency decreases diet-induced atherosclerosis.
abstract: Fatty acid metabolism is perturbed in atherosclerotic lesions, but whether it affects lesion formation is unknown. To determine whether fatty acid synthesis affects atherosclerosis, we inactivated fatty-acid synthase (FAS) in macrophages of apoE-deficient mice. Serum lipids, body weight, and glucose metabolism were the same in FAS knock-out in macrophages (FASKOM) and control mice, but blood pressure was lower in FASKOM animals. Atherosclerotic extent was decreased 20-40% in different aortic regions of FASKOM as compared with control mice on Western diets. Foam cell formation was diminished in FASKOM as compared with wild type macrophages due to increased apoAI-specific cholesterol efflux and decreased uptake of oxidized low density lipoprotein. Expression of the anti-atherogenic nuclear receptor liver X receptor alpha (LXRalpha; Nr1h3) and its downstream targets, including Abca1, were increased in FASKOM macrophages, whereas expression of the potentially pro-atherogenic type B scavenger receptor CD36 was decreased. Peroxisome proliferator-activated receptor alpha (PPARalpha) target gene expression was decreased in FASKOM macrophages. PPARalpha agonist treatment of FASKOM and wild type macrophages normalized PPARalpha target gene expression as well as Nr1h3 (LXRalpha). Atherosclerotic lesions were more extensive when apoE null mice were transplanted with LXRalpha-deficient/FAS-deficient bone marrow as compared with LXRalpha-replete/FAS-deficient marrow, consistent with anti-atherogenic effects of LXRalpha in the context of FAS deficiency. These results show that macrophage FAS deficiency decreases atherosclerosis through induction of LXRalpha and suggest that FAS, which is induced by LXRalpha, may generate regulatory lipids that cause feedback inhibition of LXRalpha in macrophages.
authors.affiliation: Department of Medicine, Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
authors.forename: Jochen G
authors.initials: JG
authors.lastname: Schneider
authors.forename: Zhen
authors.initials: Z
authors.lastname: Yang
authors.forename: Manu V
authors.initials: MV
authors.lastname: Chakravarthy
authors.forename: Irfan J
authors.initials: IJ
authors.lastname: Lodhi
authors.forename: Xiaochao
authors.initials: X
authors.lastname: Wei
authors.forename: John
authors.initials: J
authors.lastname: Turk
authors.forename: Clay F
authors.initials: CF
authors.lastname: Semenkovich
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency / Q000235:genetics; D050197:Atherosclerosis / Q000201:enzymology* / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D004032:Diet / Q000009:adverse effects*; D004198:Disease Susceptibility; D004789:Enzyme Activation; D064429:Fatty Acid Synthases / Q000172:deficiency* / Q000235:genetics / Q000378:metabolism*; D017353:Gene Deletion; D005786:Gene Expression Regulation; D055786:Gene Knockout Techniques; D050356:Lipid Metabolism; D000071518:Liver X Receptors; D008264:Macrophages / Q000201:enzymology*; D051379:Mice; D057093:Orphan Nuclear Receptors / Q000172:deficiency; D047493:PPAR alpha / Q000378:metabolism; D010641:Phenotype; D014180:Transplantation
chemical_list: D001057:Apolipoproteins E; D000071518:Liver X Receptors; C000605214:Nr1h3 protein, mouse; D057093:Orphan Nuclear Receptors; D047493:PPAR alpha; D064429:Fatty Acid Synthases